Crohn's disease clinical course and severity in obese patients
- PMID: 11884013
- DOI: 10.1054/clnu.2001.0503
Crohn's disease clinical course and severity in obese patients
Abstract
Background and aims: Obesity is unusual in Crohn's disease and the particularities of the disease in obese patients have not been studied.
Methods: 2065 patients were studied retrospectively. Obesity was defined by a BMI value >25.0 at disease onset and >30.0 at any time during the course of the disease. Disease characteristics, therapeutic needs, and year-by-year disease activity were determined in patients with and without obesity.
Results: 62 patients (3%) were obese. When compared with non-obese patients, obese patients did not show differences regarding sex, intestinal disease location, and disease behavior, but at diagnosis they were older (32 vs 28 years, P = 0.01) and a larger proportion had anoperineal disease (35 vs 24%, P = 0.03). When the 62 obese patients were paired for sex, location of disease at onset, date of birth, and date of diagnosis with 124 non-obese patients, the disease severity assessed by the importance of medical therapy and excisional surgery did not differ in the two groups but time to development of anoperineal abscess or fistula was shorter in obese patients, and obese patients were more prone to develop an active disease (OR 1.50, 95% CI 1.07-2.11) and to require hospitalization (OR 2.35, 95% CI 1.56-3.52)
Conclusion: Obesity in Crohn's disease is associated with more frequent anoperineal complications and a more marked year-by-year disease activity, but does not alter significantly the long-term course of the disease.
Copyright 2002 Elsevier Science Ltd. All rights reserved.
Similar articles
-
The impact of increased body mass index on the clinical course of Crohn's disease.Clin Gastroenterol Hepatol. 2006 Apr;4(4):482-8. doi: 10.1016/j.cgh.2005.12.015. Clin Gastroenterol Hepatol. 2006. PMID: 16616354
-
Gender-related differences in the clinical course of Crohn's disease.Am J Gastroenterol. 2001 May;96(5):1541-6. doi: 10.1111/j.1572-0241.2001.03755.x. Am J Gastroenterol. 2001. PMID: 11374696
-
Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease.Am J Gastroenterol. 2009 Nov;104(11):2754-9. doi: 10.1038/ajg.2009.387. Epub 2009 Jul 7. Am J Gastroenterol. 2009. PMID: 19584832
-
Correlation between levels of C-reactive protein and clinical activity in Crohn's disease.Dig Liver Dis. 2007 Nov;39(11):1006-10. doi: 10.1016/j.dld.2007.06.015. Epub 2007 Sep 21. Dig Liver Dis. 2007. PMID: 17889628
-
[Anoperineal manifestations of Crohn's disease].Gastroenterol Clin Biol. 2000 Jan;24(1):36-47. Gastroenterol Clin Biol. 2000. PMID: 10679586 Review. French. No abstract available.
Cited by
-
Role of Adipose Tissue in Inflammatory Bowel Disease.Int J Mol Sci. 2021 Apr 19;22(8):4226. doi: 10.3390/ijms22084226. Int J Mol Sci. 2021. PMID: 33921758 Free PMC article. Review.
-
Inflammatory bowel disease in the obese patient.Clin Colon Rectal Surg. 2011 Dec;24(4):244-52. doi: 10.1055/s-0031-1295687. Clin Colon Rectal Surg. 2011. PMID: 23204939 Free PMC article.
-
Impact of Obesity on the Course of Management of Inflammatory Bowel Disease-A Review.Nutrients. 2022 Sep 25;14(19):3983. doi: 10.3390/nu14193983. Nutrients. 2022. PMID: 36235636 Free PMC article. Review.
-
Intestinal Inflammation and Regeneration-Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease.Int J Mol Sci. 2024 Jan 21;25(2):1311. doi: 10.3390/ijms25021311. Int J Mol Sci. 2024. PMID: 38279309 Free PMC article. Review.
-
Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease.Dig Dis Sci. 2015 Aug;60(8):2436-45. doi: 10.1007/s10620-015-3629-5. Epub 2015 Mar 24. Dig Dis Sci. 2015. PMID: 25799938
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical